Trial · NCT02266433

Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

NCT02266433, Phase 3, Terminated, NYU Langone Health; results first posted 2020-11-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders. Trials, record NCT02266433. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02266433

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders
NCT number: NCT02266433
Status: Terminated
Phases: Phase 3
Enrollment: 245 participants, actual
Lead sponsor: NYU Langone Health
Conditions: DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger, Tenosynovitis, Inflammatory Disease
Interventions: Ketorolac, Dexamethasone
First posted: 2014-10-17
Last updated: 2020-11-02
Results first posted: 2020-11-02

Source ClinicalTrials.gov

Registered outcomes55

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Trigger Finger Treatment Group: EQVAS Score	Baseline	The EuroQol-visual analogue scale (EQ-VAS) is a vertical visual analogue scale that takes values between 100 (best imaginable health) and 0 (worst imaginable health), on which patients provide a global assessment of their health.
Primary	Trigger Finger Treatment Group: EQVAS Score	4 weeks	The EuroQol-visual analogue scale (EQ-VAS) is a vertical visual analogue scale that takes values between 100 (best imaginable health) and 0 (worst imaginable health), on which patients provide a global assessment of their health.
Primary	Trigger Finger Treatment Group: EQVAS Score	8 weeks	The EuroQol-visual analogue scale (EQ-VAS) is a vertical visual analogue scale that takes values between 100 (best imaginable health) and 0 (worst imaginable health), on which patients provide a global assessment of their health.
Primary	Trigger Finger Treatment Group: EQVAS Score	12 weeks	The EuroQol-visual analogue scale (EQ-VAS) is a vertical visual analogue scale that takes values between 100 (best imaginable health) and 0 (worst imaginable health), on which patients provide a global assessment of their health.
Primary	Trigger Finger Treatment Group: EQVAS Score	6 months	The EuroQol-visual analogue scale (EQ-VAS) is a vertical visual analogue scale that takes values between 100 (best imaginable health) and 0 (worst imaginable health), on which patients provide a global assessment of their health.
Primary	Trigger Finger Treatment Group: QuickDASH Functional Scores	Baseline	The QuickDASH (Quick - Disabilities of the Arm, Shoulder and Hand) is an 11-question standardized survey used to assess a patient's overall functional status and is widely used in the practice of orthopaedic surgery as an analog measurement of a patient's functional ability. Scores range from 0-100, with 100 being the most poor functionality and 0 being the best. This will be assessed at every visit by having the patient fill out the survey and our team calculating the score at the end of the visit.
Primary	Trigger Finger Treatment Group: QuickDASH Functional Scores	4 weeks	The QuickDASH (Quick - Disabilities of the Arm, Shoulder and Hand) is an 11-question standardized survey used to assess a patient's overall functional status and is widely used in the practice of orthopaedic surgery as an analog measurement of a patient's functional ability. Scores range from 0-100, with 100 being the most poor functionality and 0 being the best. This will be assessed at every visit by having the patient fill out the survey and our team calculating the score at the end of the visit.
Primary	Trigger Finger Treatment Group: QuickDASH Functional Scores	8 weeks	The QuickDASH (Quick - Disabilities of the Arm, Shoulder and Hand) is an 11-question standardized survey used to assess a patient's overall functional status and is widely used in the practice of orthopaedic surgery as an analog measurement of a patient's functional ability. Scores range from 0-100, with 100 being the most poor functionality and 0 being the best. This will be assessed at every visit by having the patient fill out the survey and our team calculating the score at the end of the visit.
Primary	Trigger Finger Treatment Group: QuickDASH Functional Scores	12 weeks	The QuickDASH (Quick - Disabilities of the Arm, Shoulder and Hand) is an 11-question standardized survey used to assess a patient's overall functional status and is widely used in the practice of orthopaedic surgery as an analog measurement of a patient's functional ability. Scores range from 0-100, with 100 being the most poor functionality and 0 being the best. This will be assessed at every visit by having the patient fill out the survey and our team calculating the score at the end of the visit.
Primary	Trigger Finger Treatment Group: QuickDASH Functional Scores	6 months	The QuickDASH (Quick - Disabilities of the Arm, Shoulder and Hand) is an 11-question standardized survey used to assess a patient's overall functional status and is widely used in the practice of orthopaedic surgery as an analog measurement of a patient's functional ability. Scores range from 0-100, with 100 being the most poor functionality and 0 being the best. This will be assessed at every visit by having the patient fill out the survey and our team calculating the score at the end of the visit.

1 to 10 of 55Source ClinicalTrials.gov

See all 55 registered outcomes

Outcomes55

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Trigger Finger Treatment Group: EQVAS Score	Baseline	Certain participants withdrew or were lost to follow up, hence the lower overall number of participants analyzed and decrease in number of participants analyzed in certain time-points.	score on a scale	MEAN
PRIMARY	Trigger Finger Treatment Group: EQVAS Score	4 weeks	Certain participants withdrew or were lost to follow up, hence the decrease in number of participants analyzed in certain time-points.	score on a scale	MEAN
PRIMARY	Trigger Finger Treatment Group: EQVAS Score	8 weeks	Certain participants withdrew or were lost to follow up, hence the decrease in number of participants analyzed in certain time-points.	score on a scale	MEAN
PRIMARY	Trigger Finger Treatment Group: EQVAS Score	12 weeks	Certain participants withdrew or were lost to follow up, hence the decrease in number of participants analyzed in certain time-points.	score on a scale	MEAN
PRIMARY	Trigger Finger Treatment Group: EQVAS Score	6 months	Certain participants withdrew or were lost to follow up, hence the decrease in number of participants analyzed in certain time-points.	score on a scale	MEAN
PRIMARY	Trigger Finger Treatment Group: QuickDASH Functional Scores	Baseline		score on a scale	MEAN
PRIMARY	Trigger Finger Treatment Group: QuickDASH Functional Scores	4 weeks	Certain participants withdrew or were lost to follow up, hence the decrease in number of participants analyzed in certain time-points	score on a scale	MEAN
PRIMARY	Trigger Finger Treatment Group: QuickDASH Functional Scores	8 weeks	Certain participants withdrew or were lost to follow up, hence the decrease in number of participants analyzed in certain time-points	score on a scale	MEAN
PRIMARY	Trigger Finger Treatment Group: QuickDASH Functional Scores	12 weeks	Certain participants withdrew or were lost to follow up, hence the decrease in number of participants analyzed in certain time-points	score on a scale	MEAN
PRIMARY	Trigger Finger Treatment Group: QuickDASH Functional Scores	6 months	Certain participants withdrew or were lost to follow up, hence the decrease in number of participants analyzed in certain time-points	score on a scale	MEAN

1 to 10 of 55Source ClinicalTrials.gov

See all 55 outcomes

Results by group92

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Trigger Finger Treatment Group: EQVAS Score	Arm Receiving Dexamethasone Injection	82.07	Standard Deviation 16.25	score on a scale
Trigger Finger Treatment Group: EQVAS Score	Arm Receiving Ketorolac Injection	82.30	Standard Deviation 13.70	score on a scale
Trigger Finger Treatment Group: EQVAS Score	Arm Receiving Dexamethasone Injection	82.79	Standard Deviation 13.48	score on a scale
Trigger Finger Treatment Group: EQVAS Score	Arm Receiving Ketorolac Injection	82.56	Standard Deviation 13.77	score on a scale
Trigger Finger Treatment Group: EQVAS Score	Arm Receiving Dexamethasone Injection	82.17	Standard Deviation 13.31	score on a scale
Trigger Finger Treatment Group: EQVAS Score	Arm Receiving Ketorolac Injection	81.61	Standard Deviation 13.65	score on a scale
Trigger Finger Treatment Group: EQVAS Score	Arm Receiving Dexamethasone Injection	93.50	Standard Deviation 6.35	score on a scale
Trigger Finger Treatment Group: EQVAS Score	Arm Receiving Ketorolac Injection	83.91	Standard Deviation 7.82	score on a scale
Trigger Finger Treatment Group: EQVAS Score	Arm Receiving Dexamethasone Injection	90.25	Standard Deviation 8.48	score on a scale
Trigger Finger Treatment Group: EQVAS Score	Arm Receiving Ketorolac Injection	75.79	Standard Deviation 14.39	score on a scale

1 to 10 of 92Source ClinicalTrials.gov

See all 92 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Arm Receiving Dexamethasone Injection	127
Overall Study	STARTED	Arm Receiving Ketorolac Injection	118
Overall Study	COMPLETED	Arm Receiving Dexamethasone Injection	68
Overall Study	COMPLETED	Arm Receiving Ketorolac Injection	65
Overall Study	NOT COMPLETED	Arm Receiving Dexamethasone Injection	59
Overall Study	NOT COMPLETED	Arm Receiving Ketorolac Injection	53

Source ClinicalTrials.gov

Adverse events4

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Skin discoloration	Skin and subcutaneous tissue disorders	Arm Receiving Dexamethasone Injection	1	127	1
other	Skin discoloration	Skin and subcutaneous tissue disorders	Arm Receiving Ketorolac Injection	0	118	0
other	Redness and itching	Skin and subcutaneous tissue disorders	Arm Receiving Dexamethasone Injection	1	127	1
other	Redness and itching	Skin and subcutaneous tissue disorders	Arm Receiving Ketorolac Injection	0	118	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Arm Receiving Dexamethasone Injection	0	127
Total, all-cause mortality	Arm Receiving Ketorolac Injection	0	118
Total, other adverse events	Arm Receiving Dexamethasone Injection	2	127
Total, other adverse events	Arm Receiving Ketorolac Injection	0	118
Total, serious adverse events	Arm Receiving Dexamethasone Injection	0	127
Total, serious adverse events	Arm Receiving Ketorolac Injection	0	118

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Arm Receiving Dexamethasone Injection vs Arm Receiving Ketorolac Injection: deaths from any cause	Trial comparisons
Arm Receiving Dexamethasone Injection vs Arm Receiving Ketorolac Injection: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02266433

GET https://conductscience.org/api/trials/v1/NCT02266433/registered?page=2

API reference For AI assistants